产品新闻

GEA introduces pharma separator lines aseptic and pure for biopharmaceutical separation processes

22 Aug 2022

With a view to the very different hygiene requirements in individual pharmaceutical processes, GEA engineers developed a new, fully comprehensive portfolio of plug & produce pharmaceutical separators. GEA presents the separator lines aseptic and pure at ACHEMA 2022 in Frankfurt. The aseptic and pure separator lines are used in all pharmaceutical and biotechnological downstream processes and meet customer-specific as well as process-required demands. GEA sees the uncompromising hygienic design reliability and the possibility of maximum yield in the respective processes as the decisive plus points of aseptic and pure.

The pharmaceutical separator lines "aseptic" and "pure" are developed to the highest GEA standards at the German GEA Westfalia Separator plant in Oelde, where they are built and tested. All features for pharmaceutical cleanliness requirements such as an automatic CIP (Cleaning-in-Place), SIP (-Sterilization-in-Place), easy validation and a high-end qualification package are included. In addition, the pharmaceutical separators support GEA customers in their quality standard reviews with the help of the cGMP validation process ("Current Good Manufacturing Practice, cGMP).

GEA separator line aseptic

The aseptic line includes SIP processing and stands for the highest hygienic pharmaceutical requirements. It offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products.

GEA's separator line aseptic including SIP offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)

GEA's separator line aseptic including SIP offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)

GEA separator line pure

The pure line gives highest variability and is perfectly tailored to the diverse process requirements of the biopharma industry. It is recommended for customers with applications with varying hygienic requirements, such as for food supplements, therapeutic proteins, pharmaceutical extractions, and in the recovery of extracellular and intracellular enzymes. Here, the separator line pure offers the highest variability in the selection of required hygienic components.

GEA presents the separator pure line at ACHEMA 2022. (Photo: GEA)

GEA presents the separator pure line at ACHEMA 2022. (Photo: GEA)

flexChange 3-in-1 bowl concept from GEA for producers with frequent product changes

The GEA flexChange 3-in-1 bowl concept of the new separator series aseptic and pure ensures high flexibility, which means a plus in competitiveness especially for Contract Manufacturing Organizations (CMO) and operators of pilot plants. The principle: the customer selects the bowl variant ideally suited to his products with solid content from 5 vol% to 35 vol% or higher, depending on product. This results in maximum yield with every product change. One GEA Pharma Skid with flexChange concept thus replaces three plants.

www.gea.com/energizing-pharma

Contact

Dr. Michael Golek

Phone: 49 211 9136 1505

Media Relations

GEA Group Aktiengesellschaft

Peter-Müller-Str. 12


40468

Düsseldorf


Germany

+49 211 9136-0

About GEA

GEA 是食品加工行业及众多工业领域的领先供应商之一,2019 年的销售总额约达 49 亿欧元。

作为国际技术集团,我们专注于机械制造,生产运营,工艺技术及其设备组件。 GEA 为各种终端用户市场的复杂生产流程提供可持续的能源解决方案,并提供全面的服务组合。集团在长期持续增长的食品和饮料行业的收入约占其总收入的 70%。截至 2018 年 12 月 31 日,集团的全球员工已超过 18,500 人。GEA 在其业务领域中是市场和技术领导者。GEA 是德国 MDAX 上市公司(G1A,WKN 660 200),拥有 STOXX® Europe 600 指数和优选的 MSCI 全球可持续发展指数。
接收 GEA 新闻

订阅 GEA 的新闻,掌握 GEA 的创新信息和故事。

联系我们

我们随时为您提供帮助!您只需提供少量详细信息,我们就能回复您的查询。